Literature DB >> 20133742

Molecular mimics can induce a nonautoaggressive repertoire that preempts induction of autoimmunity.

Emanual Maverakis1, Juscilene S Menezes, Akio Ametani, Mei Han, David B Stevens, Yong He, Yan Wang, Yoko Ono, Yoshinori Miyamura, Kit S Lam, E Sally Ward, Eli E Sercarz.   

Abstract

To determine the role that competition plays in a molecular mimic's capacity to induce autoimmunity, we studied the ability of naïve encephalitogenic T cells to expand in response to agonist altered peptide ligands (APLs), some capable of stimulating both self-directed and exclusively APL-specific T cells. Our results show that although the APLs capable of stimulating exclusively APL-specific T cells are able to expand encephalitogenic T cells in vitro, the encephalitogenic repertoire is effectively outcompeted in vivo when the APL is used as the priming immunogen. Competition as a mechanism was supported by: (i) the demonstration of a population of exclusively APL-specific T cells, (ii) an experiment in which an encephalitogenic T cell population was successfully outcompeted by adoptively transferred naïve T cells, and (iii) demonstrating that the elimination of competing T cells bestowed an APL with the ability to expand naïve encephalitogenic T cells in vivo. In total, these experiments support the existence of a reasonably broad T cell repertoire responsive to a molecular mimic (e.g., a microbial agent), of which the exclusively mimic-specific component tends to focus the immune response on the invading pathogen, whereas the rare cross-reactive, potentially autoreactive T cells are often preempted from becoming involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133742      PMCID: PMC2823870          DOI: 10.1073/pnas.0914508107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.

Authors:  R T Carson; K M Vignali; D L Woodland; D A Vignali
Journal:  Immunity       Date:  1997-09       Impact factor: 31.745

2.  Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells.

Authors:  V Kumar; V Bhardwaj; L Soares; J Alexander; A Sette; E Sercarz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

3.  Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity.

Authors:  V Bhardwaj; V Kumar; H M Geysen; E E Sercarz
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

4.  An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.

Authors:  L B Nicholson; J M Greer; R A Sobel; M B Lees; V K Kuchroo
Journal:  Immunity       Date:  1995-10       Impact factor: 31.745

5.  T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis.

Authors:  A Franco; S Southwood; T Arrhenius; V K Kuchroo; H M Grey; A Sette; G Y Ishioka
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

6.  Intramolecular mimicry. Identification and analysis of two cross-reactive T cell epitopes within a single protein.

Authors:  D T Hagerty; P M Allen
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

7.  Unresponsiveness to a self-peptide of mouse lysozyme owing to hindrance of T cell receptor-major histocompatibility complex/peptide interaction caused by flanking epitopic residues.

Authors:  K D Moudgil; I S Grewal; P E Jensen; E E Sercarz
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

8.  Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone.

Authors:  B Hemmer; B T Fleckenstein; M Vergelli; G Jung; H McFarland; R Martin; K H Wiesmüller
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

9.  Experimental autoimmune peripheral neuritis induced in BALB/c mice by myelin basic protein-specific T cell clones.

Authors:  S Abromson-Leeman; R Bronson; M E Dorf
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein.

Authors:  K W Wucherpfennig; J L Strominger
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

View more
  4 in total

1.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

2.  Jeffamine derivatized TentaGel beads and poly(dimethylsiloxane) microbead cassettes for ultrahigh-throughput in situ releasable solution-phase cell-based screening of one-bead-one-compound combinatorial small molecule libraries.

Authors:  Jared B Townsend; Farzana Shaheen; Ruiwu Liu; Kit S Lam
Journal:  J Comb Chem       Date:  2010-09-13

3.  CD4+ virtual memory: Antigen-inexperienced T cells reside in the naïve, regulatory, and memory T cell compartments at similar frequencies, implications for autoimmunity.

Authors:  Alina I Marusina; Yoko Ono; Alexander A Merleev; Michiko Shimoda; Hiromi Ogawa; Elizabeth A Wang; Kayo Kondo; Laura Olney; Guillaume Luxardi; Yoshinori Miyamura; Tilahun D Yilma; Itzel Bustos Villalobos; Jennifer W Bergstrom; Daniel G Kronenberg; Athena M Soulika; Iannis E Adamopoulos; Emanual Maverakis
Journal:  J Autoimmun       Date:  2016-11-25       Impact factor: 7.094

4.  Pathophysiology of Autoimmune Bullous Diseases: Nature Versus Nurture.

Authors:  Forum Patel; Reason Wilken; Falin B Patel; Hawa Sultani; Itzel Bustos; Christopher Duong; John J Zone; Siba P Raychaudhuri; Emanual Maverakis
Journal:  Indian J Dermatol       Date:  2017 May-Jun       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.